Scholar Rock Holding (SRRK) Cash & Equivalents (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Cash & Equivalents came in at $430.5 million in Q1 2026, up 212.16% year-on-year from $137.9 million in Q1 2025, and up 33.08% quarter-over-quarter from $323.5 million in Q4 2025.
Scholar Rock Holding (SRRK) Cash & Equivalents (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $430.5 million for Q1 2026.
- On a quarterly basis, Cash & Equivalents rose 212.16% year-over-year to $430.5 million in Q1 2026; TTM through Mar 2026 was $430.5 million, a 212.16% increase from a year earlier, with the FY2025 full-year figure at $323.5 million, up 81.88% from the prior year.
- Cash & Equivalents improved to $430.5 million in Q1 2026 per SRRK's latest filing, from $323.5 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $430.5 million in Q1 2026 and bottomed at $67.6 million in Q3 2023.
- The 5-year median for Cash & Equivalents is $133.1 million (2022), against an average of $167.2 million.
- Across the five-year window, Cash & Equivalents slumped 64.65% in 2023 and surged 275.4% in 2025, its largest moves.
- Year by year, Cash & Equivalents stood at $103.3 million in 2022, then slipped by 1.37% to $101.9 million in 2023, then soared by 74.64% to $177.9 million in 2024, then jumped by 81.88% to $323.5 million in 2025, then soared by 33.08% to $430.5 million in 2026.
- Per Business Quant, the three latest SRRK Cash & Equivalents figures stand at $430.5 million (Q1 2026), $323.5 million (Q4 2025), and $286.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | 430.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 430.54 Mn |
| Dec 31, 2025 | 323.53 Mn |
| Sep 30, 2025 | 286.77 Mn |
| Jun 30, 2025 | 152.93 Mn |
| Mar 31, 2025 | 137.93 Mn |
| Dec 31, 2024 | 177.88 Mn |
| Sep 30, 2024 | 76.39 Mn |
| Jun 30, 2024 | 93.37 Mn |
| Mar 31, 2024 | 91.98 Mn |
| Dec 31, 2023 | 101.86 Mn |
| Sep 30, 2023 | 67.60 Mn |
| Jun 30, 2023 | 108.06 Mn |
| Mar 31, 2023 | 151.28 Mn |
| Dec 31, 2022 | 103.28 Mn |
| Sep 30, 2022 | 133.08 Mn |
| Jun 30, 2022 | 305.73 Mn |
| Mar 31, 2022 | 100.18 Mn |
| Dec 31, 2021 | 212.84 Mn |
| Sep 30, 2021 | 176.13 Mn |
| Jun 30, 2021 | 206.92 Mn |